Akari Therapeutics (AKTX) Long-Term Deferred Tax (2022 - 2023)
Akari Therapeutics (AKTX) posted quarterly Long-Term Deferred Tax of $42.2 million for Q4 2023, up 22.03% year-on-year from $34.6 million in Q4 2022, and up 22.03% on a QoQ basis from $34.6 million in Q4 2022.
Akari Therapeutics (AKTX) Long-Term Deferred Tax (2022 - 2023) Analysis & Trends
Akari Therapeutics (AKTX) has reported Long-Term Deferred Tax for 2 consecutive years, with $42.2 million the latest figure, recorded in Q4 2023.
- Quarterly Long-Term Deferred Tax rose 22.03% year-over-year to $42.2 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $42.2 million (up 22.03% YoY) and the FY2023 annual result came in at $42.2 million, up 22.03% from the prior year.
- Long-Term Deferred Tax grew to $42.2 million in Q4 2023 per AKTX's latest filing, from $34.6 million in the prior quarter.
- Over the last five years, Long-Term Deferred Tax for AKTX reached as high as $42.2 million in Q4 2023 and fell as low as $34.6 million in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Akari Therapeutics | 86.55 Mn | 86.55 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 42.24 Mn |
| Dec 31, 2022 | 34.62 Mn |